Potential indications for an anti-CD7 RIT include relapsed or refractory T-ALL [36,37] and steroid-refractory acute GvHD [38,39] as well as other treatments that require T cell depletion, such as allogeneic hematopoietic stem cell transplantation (HSCT) [40,41]. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.